官网显示，以诺康成立于2014年，专注从事高端超声和眼科手术器械的研发、生产、销售和服务。公司于2021年通过国家高新技术企业认定。公司总部位于 中国(江苏)自由贸易试验区苏州片区，合肥设有生产基地和部分研发合作项目，在美国加州设有研发中心。 瑞财经 刘治颖 近日，以诺康医疗科技(苏州)股份有限公司（以下简称：以诺康）披露关于首次公开发行股票并上市辅导工作进展情况报告，华泰联合证券 为辅导机构。 辅导时间自2025年8月起至今，本期辅导进展报告的辅导时间为2025年8月至2025年9月。目前辅导工作小组由孙圣虎、王昭权、连珂、唐程伟、庞志远组 成，孙圣虎任组长。 根据辅导报告，辅导小组结合公司目前经营状况及未来发展战略规划，督促公司积极准备募投项目的相关工作、合理测算募投项目及融资规模，对募集资金 投资项目的可行性和必要性进行论证，积极推进募集资金投资项目实施方案的确定。 在高端医疗器械领域，以诺康拥有超声能量平台、电外科能量平台、眼科器械和微创手术机器人自主研发团队及核心技术，致力于高端超声、能量外科、眼 科和腹腔镜手术机器人等手术器械系统及高值耗材的研发、生产、销售与服务。截至目前，公司已申请国内专利24 ...

Core Viewpoint - Xiamen International Trade has shifted its focus towards the health technology sector after divesting from real estate, aiming to accelerate its development through mergers and acquisitions in the healthcare technology field [1][4]. Financial Performance - In the first half of 2025, Xiamen International Trade reported a revenue of 151.66 billion, a year-on-year decrease of 22.31%, and a net profit attributable to shareholders of 5.23 billion, down 37.62% [2][3]. - The supply chain management business generated 151.09 billion in revenue, with a gross margin of 1.26%, reflecting a 22.36% decline year-on-year [2][3]. - Other business segments contributed 0.24 billion in revenue, with a gross margin of 15.52%, marking a 57.57% decrease year-on-year [2][3]. - The health technology segment achieved a revenue of 5.44 billion, with a gross margin of 39.63%, down 2.62% year-on-year [2][5]. Business Strategy - The health technology segment focuses on medical devices, particularly in minimally invasive surgery, and aims to create a comprehensive service platform centered on supply chain distribution [4][5]. - The company is enhancing its elderly care services, emphasizing community and home-based care, and is developing an integrated service system that includes medical, health, and rehabilitation services [4]. - As the sole authorized health data operator for the Xiamen government, the company is building a medical big data technology platform to serve various stakeholders [4]. Recent Developments - In June 2023, Xiamen International Trade acquired Beijing Paiter Medical Technology Co., which specializes in minimally invasive surgical solutions, contributing to the health technology segment's revenue growth [5]. - Paiter Medical reported a revenue of 5.84 billion in 2024 and 2.62 billion in the first half of 2025, with net profits of 910.22 million and 556.60 million respectively [5].